Provided is a fermented milk-containing beverage for which long-term storage stability is extremely difficult, the beverage containing milk protein particles which have undergone modification in a fermentation process, wherein long-term coagulation and precipitation of the milk protein and syneresis are inhibited, perception of pastiness in terms of flavor is not present, ease of swallowing is good. This fermented milk-containing beverage contains fermented milk containing nonfat milk solids, soybean polysaccharides, and HM pectin. The nonfat milk solids content is 0.5 to 6.0 mass% with respect to the entire amount of beverage, the total content of the soybean polysaccharides and HM pectin is 0.3 to 0.8 mass% with respect to the entire amount of beverage, and the content ratio of the soybean polysaccharides and HM pectin is 3:1 to 1:4 in terms of mass ratio.
The present invention pertains to a substance or method for preventing or treating mastitis in ruminant animals, particularly in dairy cows. Specifically provided are: a ruminant-animal-mastitis preventive or therapeutic agent characterized by containing, as an active ingredient, Bacillus genus bacteria having the property of making it possible to increase or maintain CD11c+ CD172a+ blood dendritic cell gate 2 in cows; a feed additive; feed; or a drug composition.
The purpose of the invention is to provide a means for screening lactobacillus having an immunomodulatory action quickly and easily. The invention provides: a method for screening or a method for producing lactobacillus having an immunomodulatory action, including the measurement of the number of bonds of the lactobacillus being tested to uromodulin (Umod); lactobacillus obtained by this method; and a composition for immunomodulation containing this lactobacillus.
By means of the present invention, by means of including a thickening polysaccharide such as tamarind seed gum, guar gum, or HM pectin in a frozen beverage, sweetness changes or color tone changes are mitigated when drinking while melting.
The present invention elucidates a microbe which causes the occurrence an off-odour and an off-taste in acidic milk beverages having a pH of at least 3.5, and addresses the problem of providing a means for inhibiting growth of this microbe, without losing the flavour of the original beverage. According to the present invention, provided are: a growth inhibitor for bacteria belonging to genus Propionibacterium, said inhibitor including, as an active ingredient, diglycerol myristate ester and/or a salt thereof; and an acidic milky beverage which has a pH of at least 3.5, and which includes said growth inhibitor for bacteria belonging to genus Propionibacterium.
A01N 37/12 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group , wherein Cn means a carbon skeleton not containing a ringThio-analogues thereof
The present application provides: Lactobacillus gasseri strain CP2305 (FERM BP-11331), Lactobacillus gasseri strain CP2305s (NITE BP-1405), or a variant strain (e.g., a psychrotolerant variant strain) of Lactobacillus gasseri strain CP2305 (FERM BP-11331) or strain CP2305s; a method for producing the variant strain; a stress-induced bowel disorder-relieving agent which is characterized by comprising, as an active ingredient, the variant strain, a treatment product of cells of the variant strain or a mixture thereof; and a food additive, an animal additive, an animal feed and a pharmaceutical composition, each of which contains the relieving agent.
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
The present invention addresses the problem of providing an effective means for suppressing microbial growth after unsealing of a concentrated-type acidic milk beverage which includes milk. Through the present invention, there is provided a concentrated-type acidic milk beverage characterized by containing (A) milk, (B) ε-polylysine, and (C) at least one species selected from benzoic acid, a parahydroxybenzoic acid ester, and a salt thereof, the nonfat milk solid content being 1.5-4.5 wt%, and the Brix value being 40-60.
The present invention provides use of a microorganism capable of improving both lipid metabolism and sugar metabolism. Specifically, the present invention relates to: a lipid metabolism and/or sugar metabolism improver characterized by containing, as an active ingredient, a bacterial cell that has a dual-agonistic activity on a proxisome proliferator activated receptor (PPAR) α and a proxisome proliferator activated receptor (PPAR) γ and is selected from bacteria belongs to the genus Lactobacillus and the genus Bifidobacterium, a treatment product of the bacterial cell or a mixture thereof; and a food, a beverage and a pharmaceutical composition each containing the improver.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 43/00 - Drugs for specific purposes, not provided for in groups
The present application relates to a method for inducing germination in a spore-forming bacterium, and in specific terms, relates to a method for inducing germination in a spore-forming bacterium, which comprises a step for inducing germination in a spore-forming bacterium selected from the group consisting of the genus Bacillus, the genus Geobacillus, and the genus Aeribacillus using one, two, or more compounds having a phenol skeleton; an agent that induces germination, and a kit for germination of a spore-forming bacterium.
The present invention provides a simple and efficient method for producing safer chemical compounds which prevent and ameliorate conditions and ailments caused by a deterioration in brain function and are suitable for use in medicines and food products. Specifically, the present invention provides: a production method for peptides comprising an amino acid sequence set forth in one of SEQ ID NO:1-4 and 16, said method being characterized in that mammalian milk or milk protein is fermented using at least one kind of latic acid and/or a processed product thereof, and the peptides are extracted from the resultant fermented milk.
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
11.
ENZYMATIC PRODUCTION METHOD FOR BRAIN-FUNCTION-IMPROVING PEPTIDES
The present invention provides an enzymatic production method for brain-function-improving peptides. Specifically, the present invention provides a method for producing brain-function-improving peptides characterized in that milk casein is hydrolysed by enzymatic catalysts including a protease, to produce a hydrolysate including (i) peptides comprising the amino acid sequence set forth in SEQ ID NO:1 or a peptide comprising an amino acid sequence obtained by the deletion, substitution or addition of one or two amino acid residues in the amino acid sequence set forth in SEQ ID NO:1; (ii) a peptide comprising the amino acid sequence set forth in SEQ ID NO:2 or a peptide comprising an amino acid sequence obtained by the deletion, substitution or addition of one or two amino acid residues in the amino acid sequence set forth in SEQ ID NO:2; or (iii) a mixture of the peptides of (i) and (ii), with the caveat that the generation yield of each of the peptides is at least 2% or the total generation yield of the mixture is at least 10%. The present invention also provides a food product, drink, or medicinal composition including said hydrolysate.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 1/12 - General processes for the preparation of peptides by hydrolysis
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
12.
METHOD FOR MANUFACTURING CULTURE MEDIUM, AND CULTURE MEDIUM MANUFACTURED BY METHOD
Provided is a method for manufacturing a culture medium that minimizes nutrient component losses due to interactions between culture medium nutrient components, such as Maillard reactions and the like. A method for manufacturing a culture medium in order to culture microorganisms, wherein the method is characterized in comprising (1) a step for sterilizing a solution containing a sugar source raw material, (2) a step for sterilizing a solution containing a nitrogen source raw material, and (3) a step for mixing the two solutions obtained in steps (1) and (2).
C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
The present application provides: a substance having a preventative or ameliorative effect on arthritis in a subject and containing a crushed anti-inflammatory lactobacillus; a composition containing the substance; a method for producing the composition; and a method that augments the preventative or ameliorative effect on arthritis and that uses the substance.
Provided is an agent that reduces the risk of disease onset resulting from non-dipper type intra-day blood pressure fluctuations and that can reduce the onset of disease resulting from intra-day blood pressure fluctuation risk and prone to occur towards the morning when early morning systolic blood pressure significantly decreases from that of the night time in humans having a particular non-dipper type intra-day blood pressure fluctuation pattern, particularly healthy individuals exhibiting normal SBP and DBP values. The agent is characterized by containing: a hydrolysate containing VPP and IPP and obtained by hydrolyzing animal milk protein; or a concentrate thereof.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
The present invention provides a lactic acid bacterium which has high proteolysis activity and thus has excellent peptide production ability and/or amino acid production ability. The present invention also provides fermented milk which contains an amino acid and/or a peptide at high concentration and has a good flavor. The present invention specifically provides a lactic acid bacterium belonging to the genus Lactobacillus helveticus, which is characterized by having at least one of the following properties (a)-(d). (a) The lactic acid bacterium produces 25 μmol/ml or more of a free amino acid by fermenting animal milk. (b) The lactic acid bacterium produces 8.5 mg/ml or more of a peptide by fermenting animal milk. (c) The lactic acid bacterium produces XP peptide and/or XPP peptide in a total amount of 260 μg/ml or more by fermenting animal milk. (d) The amount of IPP peptide and VPP peptide per acidity of fermented milk that is obtained by fermenting animal milk at 30-34˚C (inclusive) is 6.0 mg/g or more in terms of VPP.
C12P 21/06 - Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
The present invention provides a low-dose, orally ingestible composition for enhancing brain function, and a method therefor. The present invention is a brain function enhancement composition having Phe-Pro or a salt thereof as an active ingredient.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
17.
COMPOSITION FOR IMPROVING BRAIN FUNCTION AND METHOD FOR IMPROVING BRAIN FUNCTION
The present invention provides a method, and a composition that can be taken orally in low doses, for the improvement of brain function. The present invention is a composition for the improvement of brain function having X-Pro-Pro-Y (in the formula, X represents Val, lle, or Asn-lle, and Y represents Phe or Leu) or a salt thereof as the active ingredient of the composition.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
An influenza preventative and/or therapeutic agent not requiring means such as vaccination, capable of being easily orally ingested, having no side effects even when taken long term, being very safe, and also being easily usable by the elderly and children, the influenza preventative and/or therapeutic agent containing as an active ingredient lactic acid bacteria belonging to Lactobacillus acidophilus, specifically Lactobacillus acidophilus CL-92.
Provided are an effective means and method for improving the metabolism of lipids. Also provided are a means and method for treating or preventing dyslipidemia-related diseases or disorders. Specifically provided are: a lipid metabolism-improving agent containing bacterial cell fragments of lactobacillus as an active ingredient; and method for enhancing the lipid metabolism-improving effect of lactobacillus, which includes a step for breaking down lactobacillus.
A23K 1/16 - supplemented with accessory food factors; Salt blocks
A23L 1/20 - Treatment of pulse, i.e. fruits of leguminous plants, for production of fodder or food; Preparation of products from legumes; Chemical means for rapid cooking of these foods, e.g. treatment with phosphates
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Provided is a feed-use-efficiency improver for ruminant animals, such as cows, sheep, and goats, which exerts an effect of being able to grow healthy livestock in which the rumen fermentation is improved without using antibiotic substances or special amino acids, the number of useful bacteria in the body is increased, the feed digestibility is improved, energy loss is reduced, and the feed-use efficiency and milk yield are ameliorated. Also provided are a method for improving the feed-use efficiency for ruminant animals, a method for farming ruminant animals, and a feed for ruminant animals. Specifically, provided are a feed-use-efficiency improver for ruminant animals, a method for improving the feed-use efficiency of ruminant animals, a method for farming ruminant animals, and a feed for ruminant animals, wherein the living cells of Bacillus subtilis are used as the active ingredient.
Disclosed are a method and a means for effectively increasing Lactobacillus bifidus in the colon. Specifically, disclosed is an agent that is for controlling the increase and/or decrease of L. bifidus in the colon and that contains: the spore form of Bacillus subtilus; and a means for delivering said spore form to the colon of a subject while being maintained in a spore form morphology.
Disclosed is a method for easily obtaining an immunomodulator that uses Lactobacillus cells as a starting material and that can obtain an active component with immunomodulatory activity easily and moreover in a form that is easily used in medicines and functional foods. Also disclosed is an immunomodulator obtained by means of said method. The preparation method involves a step for shaking a mixture of Lactobacillus cells and a surfactant solution and a step for separating and collecting an extract from the shaken mixture; and particularly involves a step for crushing the Lactobacillus cells, a step for concentrating the crushed bacterial cells in order to obtain a fraction comprising at least the cell membrane components of the crushed bacterial cells, a step for shaking a mixture of the obtained concentrate and the surfactant solution, and a step for separating and collecting an extract from the obtained shaken mixture.
Provided are a composition for improving the brain function, which can be orally taken at a low dose, and a method therefor. The composition for improving the brain function contains, as the active ingredient, X-Pro-Pro-Leu-Thr-Gln-Thr-Pro-Val-Val-Val-Pro-Pro-Phe-Leu-Gln-Pro-Glu-Y (wherein X is nil or represents Ile or Asn-Ile; and Y is nil or represents Val-Met), X-Val-Val-Val-Pro-Pro-Phe-Leu-Gln-Pro-Glu-Y (wherein X is nil or represents Thr-Gln-Thr-Pro, Pro-Leu-Thr-Gln-Thr-Pro, Leu-Thr-Gln-Thr-Pro or Pro; and Y is nil or represents Val-Met), or a salt of the same. The method for improving the brain function comprises administering said peptide or a salt of the same.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
24.
METHOD AND KIT FOR DETECTION OF GUAIACOL-PRODUCING BACTERIUM
Disclosed is a method for detecting a guaiacol-producing bacterium in a sample, which is characterized by comprising: carrying out plate culture of the sample of a diluted product thereof on a solid culture medium for acidophilic bacteria which contains at least one compound represented by formula (1) [wherein R represents -H, -OH, -C(O)H, -C(O)CH3, -COOH, a C1-C3 alkyl group, or a C1-C3 alkenyl group, wherein the alkyl group and the alkenyl group may be substituted by -OH, -C(O)H or -COOH]; and detecting a colony formed by the culture. In a preferred embodiment, the solid culture medium for acidophilic bacteria contains 50 ppm or more of vanilic acid, and the plate culture is carried out at 20 to 55˚C. Also disclosed are a solid culture medium for acidophilic bacteria and a kit for detecting a guaiacol-producing bacterium in a sample. The method, the solid culture medium and the kit enable the detection of a guaiacol-producing bacterium in a sample such as a fruit juice raw material rapidly and in a simple manner.
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
25.
COMPOSITION FOR REGULATING AUTONOMIC NERVOUS ACTIVITY AND METHOD FOR REGULATING AUTONOMIC NERVE
Disclosed are an orally ingestible composition and a method for regulating an autonomic nervous activity, particularly an orally ingestible composition which can prevent the increase in a sympathetic nervous activity and an orally ingestible composition which can enhance a parasympathetic nervous activity. Specifically disclosed is a composition for regulating an autonomic nervous activity, which comprises Tyr-Pro or a salt thereof as an active ingredient.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Disclosed are: a peptide and a composition each of which has an activity to inhibit the aging in the skin, an activity to promote the production of collagen, an activity to promote the turn-over of epidermides and an effect of proliferating epidermal cells and is suitable for oral ingestion; and a pharmaceutical preparation and a functional food, each of which has an activity to inhibit the aging in the skin, an activity to promote the production of collagen and an activity to promote the proliferation of epidermal cells. The composition comprises at least one peptide selected from Asn-Ile-Pro-Pro-Leu, Ile-Pro-Pro-Leu, Ile-Pro-Pro, Pro-Val-Val-Val-Pro-Pro, Val-Pro-Pro-Phe, Val-Pro-Pro, Phe-Pro-Pro-Gln and Leu-Pro-Pro-Thr.
Disclosed is an agent capable of preventing the thickening of a heart wall. Also disclosed is a prophylactic agent for heart failure or a functional food which is expected to have a prophylactic activity on heart failure, which comprises the agent capable of inhibiting the thickening of a heart wall. The agent capable of inhibiting the thickening of a heart wall comprises Xaa-Pro-Pro as an active ingredient.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 43/00 - Drugs for specific purposes, not provided for in groups
Disclosed is an agent capable of preventing a renal glomerular disease or renal arteriosclerosis. Also disclosed is a prophylactic agent for renal failure or a functional food which is expected to have a prophylactic activity on renal failure, which comprises the agent capable of preventing a renal glomerular disease or renal arteriosclerosis. The agent capable of preventing a renal glomerular disease or renal arteriosclerosis comprises Xaa-Pro-Pro as an active ingredient.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 43/00 - Drugs for specific purposes, not provided for in groups
Disclosed is a bacterium belonging to the genus Lactobacillus, which can enhance the function of a Peyer's patch to stimulate the production of IgA and can colonize in a human intestinal tract. Also disclosed is an IgA production promoter comprising a cell of the bacterium belonging to the genus Lactobacillus as an active ingredient. Specifically disclosed is an IgA production promoter comprising a cell of Lactobacillus amylovorus, particularly a cell of Lactobacillus amylovorus strain CP1750 (FERM BP-10532), as an active ingredient.
Disclosed are: an agent for inhibiting the production of active oxygen from an intestinal epithelium cell; an agent for inhibiting the production of IL-8 from an intestinal epithelium cell; and a prophylactic and therapeutic agent for inflammatory bowel disease and/or irritable bowel syndrome, each of which comprises a fermentation product, a culture supernatant and/or a culture of a bacterium belonging to the genus Bacillus as an active ingredient. The bacterium belonging to the genus Bacillus is preferably Bacillus subtilis, more preferably Bacillus subtilis C-3102 (FERM BP-1096). The agent for inhibiting the production of active oxygen from an intestinal epithelium cell, the agent for inhibiting the production of IL-8 from an intestinal epithelium cell, and the prophylactic and therapeutic agent for inflammatory bowel disease and/or irritable bowel syndrome can be administered through an oral route and are useful for the treatment and prevention of diseases including ulcerative colitis, Crohn's disease and irritable bowel syndrome.
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 43/00 - Drugs for specific purposes, not provided for in groups
It is intended to provide a miso (a seasoned soybean paste) having a favorable taste, which is expected as exerting effects of inhibiting elevation of the blood pressure and/or lowering the blood pressure when continuously taken in the daily diet, and a processed food product containing the same. It is also intended to provide a method of producing a miso whereby a peptide having an ACE inhibitory activity can be efficiently produced in the miso without deteriorating the taste qualities of the miso. In one embodiment, 10% by weight or more of animal milk casein is added in the mash step and or the fermentation/ripening step.
patents